Becker's Healthcare November 19, 2024
Andrew Cass

Private equity firms TowerBrook Capital Partners and Clayton, Dubilier & Rice have completed their $8.9 billion acquisition of R1 RCM.

With the completion of the transaction, R1’s common stock has ceased trading and will no longer be listed on Nasdaq, according to a Nov. 19 R1 RCM news release. The deal was first announced Aug. 1.

With the closing of the deal, Joe Flanagan has reassumed the role of CEO, replacing Lee Rivas. Mr. Flanagan served as R1’s CEO from May 2016 through January 2023. Mr. Flanagan has remained on the company’s board of directors since stepping down as CEO and he will continue serving on the board.

Mr. Rivas became CEO after Mr. Flanagan stepped down...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: RCM (Revenue Cycle Mgmt), Technology
Related Articles:
Trends 2025: The demand for interim revenue cycle executives
KLAS Revenue Cycle Management Summit 2024: Top Challenges and Solutions
Aspirion lands 7th acquisition in 6 years
Revenue Cycle Risk Takers
Revenue Cycle AI Is Costly and Cumbersome. Here's Why Leaders Are Still Buying In.

Share This Article